Posts for Ticker ‘BIOD’

Biodel Trades Down Close To Net Asset Value (BIOD)

If you just read headlines on Biodel Inc. (Nasdaq: BIOD) this morning, you would have thought the news coming out of the company was either good or just neutral.  Today was the exact opposite, and was an example of how dangerous it can be in merely glancing over data in biotech and emerging drug companies.  Biodel’s pivotal Phase III trials for VIAject met the primary endpoint of non-inferiority and results which demonstrated statistically significant reductions in hypoglycemic events and weight gain in Type 1 and 2 diabetes patients.  But there are problems with the data which were confusing.

Read More »

Posted on: September 8, 2008 – 3:55 pm in Biotech, Drug companies, , , , ,

The 52-Week Low Club 9/8/2008 (FRE)(FNM)(BIOD)(AUTH)(CEGE)

Sad_clownFreddie Mac (FRE) is one sale at $.65. A day-trader’s dream, down from a 52-week high of $65.88.

Fannie Mae (FNM) Almost a better deal. Sells off to $.65 from 52-week high of $68.60.

Biodel (BIOD) Concerns over drug trial. Drops to $4.34 from $25.69.

Authentec (AUTH) Revises guidance. Plunges to $2.40 from 52-week high of $19.81.

Cell Genesys (CEGE) Still hurting a week after drug trial news. Slips to $.67 from 52-week high of $4.67.

Douglas A. McIntyre

Posted on: September 8, 2008 – 2:55 pm in HI/LOW, , , , ,

Biodel & Backers Tapping Cash Via Equity Sale (BIOD)

Biodel Inc. (NASDAQ: BIOD) has filed with the SEC to sell up to 8.5 million shares of common stock.  The company will sell 5.5 million of the shares and 3 million of the shares being sold will come from shareholders who were pre-IPO backers of the company..

The company will use the proceeds it receives for general corporate purposes, but it will not receive any proceeds of the shares being sold by shareholders.  The firm did not list formal underwriters for the offering.  Shares are trading down roughly 8% pre-market at $17.00 and the 52-week trading range is $9.60 to $25.69.

Jon C. Ogg
August 25, 2008

Posted on: August 25, 2008 – 7:45 am in Biotech, Secondary Offering,

Top 10 Pre-Market Analyst Calls (ABX, BIOD, FTK, GLNG, OSG, TEF, PAR, UPL, XLNX)

Below are the top 10 individual analyst calls we are focusing on this morning:

  • Barrick Gold (NYSE: ABX) downgraded to neutral at Credit Suisse.
  • Biodel (NASDAQ:    BIOD) started as Overweight at JPMorgan.
  • Flotek Ind. (NYSE: FTK) started as Outperform at bear Stearns.
  • Golar LNG (NASDAQ: GLNG) downgraded to Hold at Jefferies and downgraded to Market Perform at FBR.
  • Overseas Shipholding (NYSE: OSG) raised to Outperform at Bear Stearns.
  • Telefonica SA (NYSE: TEF) raised to Buy at UBS.
  • 3Par (NYSE: PAR) started as Buy at Merriman Curhan Ford.
  • Ultra Petroleum (NYSE: UPL) downgraded to Neutral at JPMorgan.
  • Xilinx (NASDAQ: XLNX) raised to Buy at UBS.

Jon C. Ogg
February 27, 2008

Posted on: February 27, 2008 – 7:55 am in Analyst Calls, , , , , , , , ,